Asthma and chronic obstructive pulmonary disease (COPD) are lung diseases that cause extensive illness and death. Both diseases involve infiltration of damaging inflammatory cells. We found that sugar molecules (glycans) on lung tissues engage sugar binding proteins (siglecs) on inflammatory cells, signaling them to stop and limiting tissue damage. The goal of the Lung Inflammatory Disease Program of Excellence in Glycosciences (LID-PEG) is to develop new ways to treat asthma and COPD based on siglec-glycan binding
The LID-PEG is comprised of four highly-integrated projects supported by two scientific cores (carbohydrate chemistry and animal disease models) that together span five leading biomedical research institutions (Johns Hopkins, Northwestern, The Scripps Research Institute, Unviersity of Georgia, and Yale). In addition, the LID-PEG is committed to training younger investigators to be the future leaders in biomedical glycosciences.
The LID-PEG team welcomes your interest and invites you to explore our site. Please contact us with questions or comments.
Ronald L. Schnaar
LID-PEG Program Director
- Johns Hopkins School of Medicine
Department of Pharmacology
& Molecular Sciences
725 N. Wolfe Street, WBSB 321
Baltimore, MD 21205
- Phone: 410-955-8467